Uma B. Dasgupta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Uma B. Dasgupta has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Bama Charan Mondal
Cytogenetics Laboratory, Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi 221005, India
4 shared publications Aditi Bandyopadhyay
Department of Biophysics, Molecular Biology and Genetics, University of Calcutta, Kolkata, India
2 shared publicationsAshis Mukhopadhyay
Kothari Medical Centre, Kolkata, India
2 shared publicationsSharmila Chandra
Department of Biophysics, Molecular Biology and Genetics, Calcutta University>, 2Department of Chemistry, Calcutta University, Calcutta, India, 3Department of Haematology, Kothari Medical Centre, Kolkata, and 4Department of Haematology, School of Tropical Medicine, Kolkata, India
2 shared publicationsSunipa Majumdar
Department of Biophysics, Molecular Biology and Genetics, University of Calcutta, Kolkata, India
2 shared publicationsUtpal Chaudhuri
Institute of Haematology and Transfusion Medicine, Kolkata, India
2 shared publications
Latest Publications
- 14 July 2008
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 146A (15) , 1980-1985
Haplotype analysis at the FRAXA locus in an Indian population
The FRAXA locus is flanked by three polymorphic STR markers DXS548, FRAXAC1, and FRAXAC2. Allele frequencies of these markers were determined on a population representing the eastern part of India comprising of 69 normal controls and 69 unrelated subjects with mental retardation, among whom 21 were fragile X patients. These frequencies were compared with published data on other Indian population and the major populations of the world. The allele and haplotype distribution of the studied population were significantly different in some respects from the major populations of the world. The increase of heterozygosities in fragile X samples (DXS548 67.5%, FRAXAC1 63.5%, FRAXAC2 68.5%) relative to the controls (DXS548 63.3%, FRAXAC1 51.0%, FRAXAC2 67.2%) suggests a multimodal distribution of fragile X associated alleles. Haplotype analyses with DXS548 and FRAXAC1 markers revealed that haplotype distribution in the normal controls and fragile X groups were significantly different, suggesting a weak founder effect.
- 14 July 2008
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 146A (15) , 1980-1985
Haplotype analysis at the FRAXA locus in an Indian population
The FRAXA locus is flanked by three polymorphic STR markers DXS548, FRAXAC1, and FRAXAC2. Allele frequencies of these markers were determined on a population representing the eastern part of India comprising of 69 normal controls and 69 unrelated subjects with mental retardation, among whom 21 were fragile X patients. These frequencies were compared with published data on other Indian population and the major populations of the world. The allele and haplotype distribution of the studied population were significantly different in some respects from the major populations of the world. The increase of heterozygosities in fragile X samples (DXS548 67.5%, FRAXAC1 63.5%, FRAXAC2 68.5%) relative to the controls (DXS548 63.3%, FRAXAC1 51.0%, FRAXAC2 67.2%) suggests a multimodal distribution of fragile X associated alleles. Haplotype analyses with DXS548 and FRAXAC1 markers revealed that haplotype distribution in the normal controls and fragile X groups were significantly different, suggesting a weak founder effect.
- 1 November 2006
- Published by Wiley in American Journal of Hematology
- Vol. 81 (11) , 845-849
Molecular profiling of chronic myeloid leukemia in eastern India
Molecular breakpoint of the BCR‐ABL fusion gene has been characterized for 122 chronic myeloid leukemia patients. Out of 122 cases, 33 b2a2, 69 b3a2, 2 e1a2, and 2 e19a2 cases have been detected. Six coexpressed both b2a2 and b3a2 transcripts. All the coexpressing samples had an A>G polymorphism at the putative splice branchpoint in intron 13. The T>C polymorphism in exon 13, reported to be linked to coexpression, was not present in all the coexpressing patients. No correlation of transcript type with platelet count was detected. Those expressing b2a2 transcript were diagnosed at relatively younger age and with higher white blood cell count, in agreement with other reports. However, the correlation was not statistically significant. Am. J. Hematol., 2006.
- 1 November 2006
- Published by Wiley in American Journal of Hematology
- Vol. 81 (11) , 845-849
Molecular profiling of chronic myeloid leukemia in eastern India
Molecular breakpoint of the BCR‐ABL fusion gene has been characterized for 122 chronic myeloid leukemia patients. Out of 122 cases, 33 b2a2, 69 b3a2, 2 e1a2, and 2 e19a2 cases have been detected. Six coexpressed both b2a2 and b3a2 transcripts. All the coexpressing samples had an A>G polymorphism at the putative splice branchpoint in intron 13. The T>C polymorphism in exon 13, reported to be linked to coexpression, was not present in all the coexpressing patients. No correlation of transcript type with platelet count was detected. Those expressing b2a2 transcript were diagnosed at relatively younger age and with higher white blood cell count, in agreement with other reports. However, the correlation was not statistically significant. Am. J. Hematol., 2006.
- 4 October 2006
- Published by BMJ in Journal of Clinical Pathology
- Vol. 59 (10) , 1102-1103
e19a2 BCR–ABL fusion transcript in typical chronic myeloid leukaemia: a report of two cases: Figure 1
This report describes two patients with chronic myeloid leukaemia (CML): one of them developed accelerated phase CML and died 8 years after diagnosis and the other is at the chronic phase. Sequence analysis of reverse transcription-polymerase chain reaction products showed the presence of BCR–ABL fusion transcript e19a2. This finding suggests that CML carrying μ-BCR breakpoint may exhibit a clinical course similar to typical CML.
- 4 October 2006
- Published by BMJ in Journal of Clinical Pathology
- Vol. 59 (10) , 1102-1103
e19a2 BCR–ABL fusion transcript in typical chronic myeloid leukaemia: a report of two cases: Figure 1
This report describes two patients with chronic myeloid leukaemia (CML): one of them developed accelerated phase CML and died 8 years after diagnosis and the other is at the chronic phase. Sequence analysis of reverse transcription-polymerase chain reaction products showed the presence of BCR–ABL fusion transcript e19a2. This finding suggests that CML carrying μ-BCR breakpoint may exhibit a clinical course similar to typical CML.
- Open Access
- 26 October 2005
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 89 (2) , 431-437
DNA Hypermethylation of Promoter of Gene p53 and p16 in Arsenic-Exposed People with and without Malignancy
Chronic arsenic exposure is known to produce arsenicosis and cancer. To ascertain whether perturbation of methylation plays a role in such carcinogenesis, the degree of methylation of p53 and p16 gene in DNA obtained from blood samples of people chronically exposed to arsenic and skin cancer subjects was studied. Methylation-specific restriction endonuclease digestion followed by polymerase chain reaction (PCR) of gene p53 and bisulfite treatment followed by methylation-sensitive PCR of gene p16 have been carried out to analyze the methylation status of the samples studied. Significant DNA hypermethylation of promoter region of p53 gene was observed in DNA of arsenic-exposed people compared to control subjects. This hypermethylation showed a dose-response relationship. Further, hypermethylation of p53 gene was also observed in arsenic-induced skin cancer patients compared to subjects having skin cancer unrelated to arsenic, though not at significant level. However, a small subgroup of cases showed hypomethylation with high arsenic exposure. Significant hypermethylation of gene p16 was also observed in cases of arsenicosis exposed to high level of arsenic. In man, arsenic has the ability to alter DNA methylation patterns in gene p53 and p16, which are important in carcinogenesis.
- 26 October 2005
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 89 (2) , 431-437
Open AccessDNA Hypermethylation of Promoter of Gene p53 and p16 in Arsenic-Exposed People with and without Malignancy
Chronic arsenic exposure is known to produce arsenicosis and cancer. To ascertain whether perturbation of methylation plays a role in such carcinogenesis, the degree of methylation of p53 and p16 gene in DNA obtained from blood samples of people chronically exposed to arsenic and skin cancer subjects was studied. Methylation-specific restriction endonuclease digestion followed by polymerase chain reaction (PCR) of gene p53 and bisulfite treatment followed by methylation-sensitive PCR of gene p16 have been carried out to analyze the methylation status of the samples studied. Significant DNA hypermethylation of promoter region of p53 gene was observed in DNA of arsenic-exposed people compared to control subjects. This hypermethylation showed a dose-response relationship. Further, hypermethylation of p53 gene was also observed in arsenic-induced skin cancer patients compared to subjects having skin cancer unrelated to arsenic, though not at significant level. However, a small subgroup of cases showed hypomethylation with high arsenic exposure. Significant hypermethylation of gene p16 was also observed in cases of arsenicosis exposed to high level of arsenic. In man, arsenic has the ability to alter DNA methylation patterns in gene p53 and p16, which are important in carcinogenesis.
- Open Access
- 6 April 2005
- Published by Wiley in British Journal of Haematology
- Vol. 129 (2) , 282-286
Co‐inheritance of the Hb Sun Prairie mutation with a point mutation at 5′‐UTR in the eastern Indian population
Haemoglobin (Hb) Sun Prairie (alpha2-globin cd130, GCT-->CCT, Ala-->Pro) is detected in three unrelated chromosomes, in association with a C-->T transition in the 5'-untranslated region (UTR), two bases upstream from the translation start site. Reported inversion of alpha/beta-mRNA ratio observed in Hb Sun Prairie mutants might stem from the second mutation and should be investigated. Molecular modelling studies indicate that the 130th residue of alpha-globin faces primarily the central cavity of the molecule and is not in contact with any beta-chain residue; further, no significant disruption of the Hb structure because of the Sun Prairie mutation is discernible. Depression of translation because of the second mutation of a conserved base in the 5'-UTR might explain the observed clinical severity.
- 6 April 2005
- Published by Wiley in British Journal of Haematology
- Vol. 129 (2) , 282-286
Open AccessCo‐inheritance of the Hb Sun Prairie mutation with a point mutation at 5′‐UTR in the eastern Indian population
Haemoglobin (Hb) Sun Prairie (alpha2-globin cd130, GCT-->CCT, Ala-->Pro) is detected in three unrelated chromosomes, in association with a C-->T transition in the 5'-untranslated region (UTR), two bases upstream from the translation start site. Reported inversion of alpha/beta-mRNA ratio observed in Hb Sun Prairie mutants might stem from the second mutation and should be investigated. Molecular modelling studies indicate that the 130th residue of alpha-globin faces primarily the central cavity of the molecule and is not in contact with any beta-chain residue; further, no significant disruption of the Hb structure because of the Sun Prairie mutation is discernible. Depression of translation because of the second mutation of a conserved base in the 5'-UTR might explain the observed clinical severity.
- 15 December 2004
- Published by Wiley in Prenatal Diagnosis
- Vol. 24 (12) , 992-996
Profile of β‐thalassemia in eastern India and its prenatal diagnosis
Objective: To control the birth of thalassemic children in India.Methods: Mutations present in the population of eastern India and in carrier parents seeking prenatal diagnosis were detected by the PCR‐based technique of ARMS (amplification refractory mutation system) or gap‐PCR. To screen for maternal tissue contamination in CVS, haplotypes associated with the β‐globin gene clusters were constructed using six polymorphic restriction sites. Prenatal diagnosis was accomplished by checking presence of parental mutation in the DNA from chorionic villus sampling (CVS) collected at 8 to 10 weeks' gestation by appropriate technique.Results: Six hundred and fifty (650) unrelated β‐thalassemia chromosomes were screened for 11 common mutations to characterize the mutation distribution in this population. Starting from early 2000, 63 families from different parts of West Bengal and from surrounding areas have been offered prenatal counseling for β‐thalassemia.Conclusion: The population of this region is conscious and willing to accept prenatal diagnosis as a means of control of thalassemia. Copyright © 2004 John Wiley & Sons, Ltd.
- 15 December 2004
- Published by Wiley in Prenatal Diagnosis
- Vol. 24 (12) , 992-996
Profile of β‐thalassemia in eastern India and its prenatal diagnosis
Objective: To control the birth of thalassemic children in India.Methods: Mutations present in the population of eastern India and in carrier parents seeking prenatal diagnosis were detected by the PCR‐based technique of ARMS (amplification refractory mutation system) or gap‐PCR. To screen for maternal tissue contamination in CVS, haplotypes associated with the β‐globin gene clusters were constructed using six polymorphic restriction sites. Prenatal diagnosis was accomplished by checking presence of parental mutation in the DNA from chorionic villus sampling (CVS) collected at 8 to 10 weeks' gestation by appropriate technique.Results: Six hundred and fifty (650) unrelated β‐thalassemia chromosomes were screened for 11 common mutations to characterize the mutation distribution in this population. Starting from early 2000, 63 families from different parts of West Bengal and from surrounding areas have been offered prenatal counseling for β‐thalassemia.Conclusion: The population of this region is conscious and willing to accept prenatal diagnosis as a means of control of thalassemia. Copyright © 2004 John Wiley & Sons, Ltd.